Can AI models accurately read molecular structures, interpret wet-lab findings, and select viable drug candidates?
OpenAI introduced MedChemBench, a benchmark designed to evaluate how large language models handle complex reasoning tasks from medicinal chemistry research. The benchmark measures model capability across 99 problems drawn from published research, encompassing 117 scientific papers and patents alongside 761 distinct molecular structures. Across these tasks, systems receive real program context—including biological targets, research objectives, previously studied compounds, and selected experimental findings—to determine whether AI can advance beyond promotional narratives into measurable laboratory utility. The central operational question facing research teams is whether current model architectures can handle real biochemical trade-offs or remain unreliable at calculating physical properties.
Four Pillars of Chemical Evaluation
To establish an objective baseline, MedChemBench separates chemical problem-solving into four distinct components: molecular structures, scientific reasoning, ranking and selection, and property predictions. Structural evaluation requires assembling molecules from drawings and chemical groups while preserving correct atom connections and stereochemistry. Reasoning focuses on explanations supported by empirical evidence, such as justifying why one compound warrants development over another. Ranking and selection tests compound choices against project constraints, while property predictions assess how closely model outputs match reported numerical metrics.
"One of the hardest parts of this work is that improving one property of a molecule can make another worse."
In drug discovery, a molecule might exhibit potent binding against a disease-related protein yet fail because it is poorly absorbed or breaks down rapidly in living tissue. For automated systems to provide tangible value, they must map structural modifications directly to experimental behavior rather than optimizing single variables in isolation. How do frontier models perform when forced to balance conflicting biological demands?
A practical case study within the benchmark demonstrates the challenge using inhibitors of PRMT5, an established protein target in cancer research. Models receive earlier structures and data, then attempt to predict three concurrent properties across related compounds: PRMT5 cellular inhibition, cellular barrier permeability, and liver-enzyme metabolic breakdown rates. In experimental data withheld during testing, compound 23 blocked PRMT5 at a lower concentration, whereas compound 24 crossed cell barriers more readily and broke down more slowly in liver-enzyme assays. Handling such multi-parameter trade-offs proves whether a model understands real molecular interactions.
Benchmark Performance and Architectural Limits
At the shared xhigh reasoning setting across eleven evaluated models, GPT-6.2 Astra achieved 84.5% of available credit, compared with 83.3% for GPT-6 Astra, 82.0% for GPT-6.1 Sol, and 58.2% for GPT-5.6 Sol. Although higher reasoning settings improved performance across the board, wide performance gaps persisted between different model families.
Structural representation remains the foundation where older architectures stumble. In an assembly task requiring models to join a central core and two chemical groups into an 18-atom ring, GPT-6 Astra solved the problem correctly across all ten test runs at xhigh, earning 95.4% credit on structural components. In contrast, GPT-5.6 Sol and GPT-5.6 Luna failed all ten attempts, with GPT-5.6 Sol assembling an incorrect 15-atom ring and GPT-5.6 Luna fragmenting the molecule into disconnected parts. Misidentifying atomic connectivity invalidates downstream analysis before property evaluation even begins.
While GPT-6 Astra proved strongest at reconstructing molecular configurations and explaining empirical evidence, selecting optimal compounds and predicting numerical values remained difficult bottlenecks. Current reasoning architectures demonstrate high competence at parsing chemical literature and preserving structural representations, yet exact property forecasting remains a distinct technical barrier. Verification through standardized, multi-variable benchmarks provides the primary filter separating deployable synthesis planning from speculative claims.
What doesn’t add up
The financial risk of wasting research budgets on biologically unviable molecules shrinks as OpenAI's MedChemBench pins model reasoning directly against real-world lab patents. Behind the benchmark metrics lies an operational trade-off: an architecture must either balance mutually conflicting metrics like cellular permeability against liver enzyme breakdown, or fail at basic physics. High reasoning compute finally makes complex bio-assembly workable rather than a lottery, turning theoretical chemical diagrams into verifiable predictions. According to the company, GPT-5.6 Sol secured only 58.2% of points, while GPT-6.2 Astra reached 84.5% under maximum reasoning depth.